ArticleJAMA network open2026
Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with early death from de novo metastatic breast cancer in Ontario, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Importance: In the US, patients from minoritized racial and ethnic groups generally receive diagnoses at later stages of breast cancer, face care barriers, and experience worse outcomes, despite advances in screening and treatment. There remain limited data on disparities in presentation and treatment initiation timing for de novo metastatic breast cancer (dnMBC) nationally. Objective: To examine patterns of disease presentation and treatment initiation for dnMBC by race and ethnicity. Design, Setting, and Participants: This study is a retrospective cross-sectional analysis of the 2010 to 2022 National Cancer Database evaluating presentation and treatment differences in 3 main subtypes: hormone receptor (HR)-positive and epidermal growth factor receptor 2 (ERBB2)-negative, ERBB2-positive, and triple-negative breast cancer (TNBC). Data were analyzed from March to September 2025. Exposure: Diagnosis of dnMBC. Main Outcomes and Measures: Metastatic sites were categorized as brain, bone only, and visceral (ie, liver and/or lung). Treatment modalities were categorized as chemotherapy, endocrine therapy, ERBB2-directed therapy, immunotherapy, and radiotherapy. Treatment initiation timing was defined as days between diagnosis and treatment start, modeled using multiple linear regression. Results: Among 117 743 female patients with dnMBC (mean [SD] age, 62.0 [14.1] years; 4271 [3.7%] Asian or Pacific Islander, 20 153 [17.3%] Black, 7785 [6.7%] Hispanic, and 83 337 [71.3%] White), 72 874 (61.9%) had HR-positive-ERBB2-negative disease, 27 972 (23.8%) had ERBB2-positive disease, and 16 897 (14.3%) had TNBC. In the HR-positive-ERBB2-negative cohort, higher proportions of Black and Hispanic patients presented with brain metastases; White patients more commonly presented with bone-only metastases. Compared with White patients, Black patients experienced longer days to endocrine therapy initiation (β, 6.6; 95% CI, 4.5-8.8), chemotherapy (β, 3.6; 95% CI, 1.4-5.8), and radiotherapy (β, 11.3; 95% CI, 5.9-16.7). Similar delays occurred among Asian or Pacific Islander and Hispanic patients. In the ERBB2-positive cohort, bone-only metastases were more common among White patients. Black patients experienced longer ERBB2-directed therapy initiation timing (β, 5.7; 95% CI, 2.9-8.6) and chemotherapy (β, 5.1; 95% CI, 0.1-10.1) than White patients; Hispanic patients also experienced delays. Among patients with TNBC, bone-only metastases were higher among Asian or Pacific Islander patients, brain metastases were higher among White patients, and visceral metastases were higher among Black patients. Compared with White patients, Black (β, 7.8; 95% CI, 0.6-15.1) and Hispanic (β, 16.6; 95% CI, 6.0-27.2) patients experienced longer times to immunotherapy initiation, although the difference was no longer significant after socioeconomic covariate adjustment. Living in lower-income and lower-education areas and use of public or lack of insurance were associated with heterogeneous delays across subtypes and treatment modalities. Conclusions and Relevance: This cross-sectional study of patients with dnMBC found racial and ethnic disparities in disease presentation and inequities in timely treatment for dnMBC across subtypes, emphasizing the need for tailored interventions to improve care delivery and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.